Imiquimod
Pronunciation: (ih-MIH-kwih-mod).
- Generic name
- Imiquimod
- Brand names
- Aldara, Zyclara, Vyloma, Imutrex, Imiquimod Sandoz, Imiquimod
- Drug class
- Immune Response Modifier (Topical Immunomodulator)
Availability and supply rules vary by country
Trade names by country: United States · Canada
Australia: · Full directory
What Imiquimod is and how it works
Uses, formulations, monitoring, and supply rules can differ by patient, product, and country. Follow the exact local product information and professional advice.
Mechanism of action: how Imiquimod works
Imiquimod is a toll-like receptor 7 (TLR7) agonist that stimulates innate and adaptive immune responses. It induces the production of cytokines such as interferon-alpha, tumor necrosis factor-alpha, and interleukins, enhancing the body's ability to clear abnormal cells and viral infections. (1)
What Imiquimod is used for
External genital and perianal warts
External genital and perianal warts
Actinic keratosis on the face or scalp
Actinic keratosis on the face or scalp
Superficial basal cell carcinoma
Superficial basal cell carcinoma
Before taking Imiquimod
Do not take / not appropriate for
- The US prescribing information for ZYCLARA lists no contraindications — section 4 of the label reads "None." The limits on using this cream are set out as warnings and precautions rather than as absolute contraindications, so read those and follow the prescriber's instructions. (all countries)
- Do not put ZYCLARA in the eyes, on the lips or in the nostrils, or inside the anus or vagina — it is for topical use on the skin only. If it does reach those areas, rinse with water straight away. (all countries)
Tell your clinician about
- If you are allergic to imiquimod, to any ingredient of the cream, or to other medicines, foods, or substances — say what the reaction was.
- If you are using any other imiquimod product on the same area, as this can make local skin reactions more likely and more severe.
- If you have an inflammatory skin condition, including chronic graft-versus-host disease, which this cream can worsen.
How to take Imiquimod
- General Instructions: Apply a thin layer to the affected area as prescribed, usually once daily before bedtime. Wash hands before and after application.. Adult Dosing: For actinic keratosis: Apply once daily to the affected area for 2 weeks, then take a 2-week break, and repeat if needed. For genital warts: Apply once daily until warts clear, up to 8 weeks. For superficial basal cell carcinoma: Apply once daily for 6 weeks.. Pediatric Dosing: Safety and efficacy in children under 12 years have not been established. Use only if prescribed by a pediatric specialist.. Administration: Apply to clean, dry skin. Do not cover with airtight dressings. Leave on skin for 8 hours, then wash off with mild soap and water.. When To Seek Review: Seek medical advice promptly if severe skin reactions, allergic symptoms, or signs of infection develop; let the clinician you see advise on whether to continue or ask the prescriber about stopping it. Consult your provider if no improvement after the full course.. Storage: Store at room temperature (20–25°C/68–77°F), away from moisture and heat. Keep out of reach of children.
- This page does not provide a dose calculator. Dosing must follow the prescriber, pharmacist, or product label.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician.
Missed dose
If you miss a dose, apply it as soon as you remember. If it is almost time for your next dose, contact your prescriber or pharmacist for guidance on the missed dose and resume your regular schedule. Do not apply extra cream to make up for a missed dose.
Overdose
Accidental overdose is unlikely with topical use. If large amounts are applied or ingested, seek medical attention immediately. Symptoms may include severe skin irritation, headache, nausea, or systemic effects.
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms to a healthcare professional.
Skin irritation/redness/itching/burning at application site
Incidence: Reported in the clinician-authored database; frequency not established
Flaking/scaling/crusting of skin
Incidence: Reported in the clinician-authored database; frequency not established
Scabbing/ulceration of skin
Incidence: Reported in the clinician-authored database; frequency not established
Swelling at application site
Incidence: Reported in the clinician-authored database; frequency not established
Headache
Incidence: Reported in the clinician-authored database; frequency not established
Flu-like symptoms (fever, body aches)
Incidence: Reported in the clinician-authored database; frequency not established
Changes in skin color (hypopigmentation or hyperpigmentation)
Incidence: Reported in the clinician-authored database; frequency not established
Warning sign
What to notice: Severe skin reactions (blistering, ulceration, intense pain) Swelling of the face, lips, or tongue Difficulty breathing or swallowing Unusual tiredness or weakness Fever or flu-like symptoms that do not improve
What to do: Seek immediate medical attention if you experience severe allergic reactions (anaphylaxis), persistent or worsening skin reactions, signs of infection (pus, spreading redness), or systemic symptoms such as high fever, muscle aches, or swollen lymph nodes. (1)
Serious warnings
For external use only — serious
Symptoms: For external use only; avoid eyes, mouth, and mucous membranes. May cause local skin reactions; monitor for severe irritation. Use caution in immunocompromised patients. Not recommended during pregnancy unless clearly needed. Do not use on open wounds or severely inflamed skin.
Action: Follow the urgency stated and seek prompt or emergency care when indicated.
Contraindications recorded in the clinician database — serious
Symptoms: Contraindications recorded in the clinician database: Contraindicated in patients with known hypersensitivity to imiquimod or formulation components. Use with caution in immunocompromised individuals, patients with autoimmune disorders, and those with a history of severe local skin reactions.
Action: Follow the urgency stated and seek prompt or emergency care when indicated.
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Recorded interactions | There are no major drug-drug interactions reported with topical imiquimod. However, avoid using other topical medications, harsh cleansers, or irritants on the same area unless advised by your healthcare provider. Systemic immunosuppressants may reduce the effectiveness of imiquimod. | (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
Pregnancy Category B; use only if clearly needed and the benefits outweigh the risks.
Breastfeeding
It is not known whether Imiquimod is excreted in human milk; caution should be exercised.
Children
Frequency: Not applicable.. Weight Based: Not recommended for pediatric use.. Max Daily Dose: Not applicable.. Max Single Dose: Not applicable.. Age Restrictions: Safety not established in children.
Renal_impairment
Renal impairment: No specific dosing adjustments are required for patients with renal impairment. Hepatic impairment: No specific dosing adjustments are required for patients with hepatic impairment. Elderly: No specific dosage adjustments are necessary; however, caution is advised.
Hepatic_impairment
Renal impairment: No specific dosing adjustments are required for patients with renal impairment. Hepatic impairment: No specific dosing adjustments are required for patients with hepatic impairment. Elderly: No specific dosage adjustments are necessary; however, caution is advised.
Monitoring
Storage
Store at 25°C (77°F); short excursions between 15–30°C (59–86°F) are permitted. Do not freeze. Store pump bottles upright. Discard the pump bottle after finishing a treatment course, and discard partially used packets — do not reuse them. Keep out of reach of children.
Professional information
Clinician-facing context only. This section does not replace current product labeling.
General
Indication: External genital and perianal warts
Dose summary: Apply a thin layer of Zyclara (Imiquimod cream) to the affected area once daily at bedtime.
Renal context: No specific dosing adjustments are required for patients with renal impairment. (1)
Frequently asked questions
How long does it take for Zyclara (Imiquimod cream) to work?
Improvement is usually seen within a few weeks of starting treatment, but full clearance may take up to 8 weeks depending on the condition being treated.
Can I use Zyclara on my face?
Zyclara can be used on the face for actinic keratosis or superficial basal cell carcinoma if prescribed by your doctor. Avoid contact with eyes, nostrils, and lips.
What should I do if I experience severe skin irritation?
seek medical advice promptly, and let the clinician you see advise on whether to continue or stop the cream, blistering, pain, or swelling.
Is Zyclara safe during pregnancy or breastfeeding?
Safety in pregnancy and breastfeeding is not well established. Use only if clearly needed and prescribed by your doctor.
Can I cover the treated area with a bandage?
Do not use airtight or occlusive dressings over the treated area. Loose clothing is acceptable.
Are there any foods or drinks I should avoid while using Zyclara?
There are no known food or drink restrictions. However, avoid alcohol if you experience significant skin irritation.
Can I use other skin products with Zyclara?
Avoid using other topical medications, cosmetics, or harsh cleansers on the treated area unless directed by your healthcare provider.
What happens if I take too much Zyclara (Imiquimod cream)?
Applying too much Zyclara cream may increase the severity of local skin reactions, such as redness, swelling, and itching at the application site. While systemic overdose is unlikely with topical application, if you experience severe skin reactions or any unusual symptoms, wash off the excess cream and contact your healthcare provider immediately. In case of accidental ingestion, seek emergency medical help.
Can I drink alcohol while taking Zyclara (Imiquimod cream)?
There are no known direct interactions between Zyclara (Imiquimod cream) and alcohol. However, alcohol consumption can sometimes exacerbate skin conditions or cause dehydration, which might indirectly affect skin health. It's generally advisable to discuss your alcohol intake with your healthcare provider, especially if you are undergoing treatment for a dermatological condition, to ensure it doesn't interfere with your recovery or treatment efficacy.
Is Zyclara (Imiquimod cream) safe during pregnancy?
Zyclara (Imiquimod cream) is categorized as 'Consult doctor' for use during pregnancy. This means that its safety in pregnant women has not been definitively established. It is crucial to inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding before using Zyclara. Your doctor will weigh the potential benefits against any potential risks to determine the most appropriate course of action for your specific situation.
What is the mechanism of action of Imiquimod?
Imiquimod is a toll-like receptor 7 (TLR7) agonist that stimulates innate and adaptive immune responses. It induces the production of cytokines such as interferon-alpha, tumor necrosis factor-alpha, and interleukins, enhancing the body's ability to clear abnormal cells and viral infections. (1)
What is the generic name of Imiquimod?
The generic name is Imiquimod. It is sold under brand names including Aldara, Zyclara, Vyloma, Imutrex, Imiquimod Sandoz, Imiquimod.
What class of drug is Imiquimod?
Imiquimod is classed as: Immune Response Modifier (Topical Immunomodulator).
References
- Zyclara (Imiquimod cream) — MedGuideGlobal clinician-authored medicine recordMedGuideGlobal · Not applicable (internal clinician-authored record) · accessed 2026-08-07 · source 1
- ZYCLARA (imiquimod) cream, for topical use — Prescribing Information (DailyMed)DailyMed, U.S. National Library of Medicine · United States · accessed 2026-08-08 · source 2
- ZYCLARA (IMIQUIMOD) CREAM [BAUSCH HEALTH US, LLC] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 3
- Imiquimod Topical — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 4
- Imiquimod — FDA approval record (Drugs@FDA ANDA078837)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 5
- Imiquimod — RxNorm normalized drug concept (RXCUI 59943)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 6
Brand names by country
Single-ingredient Imiquimod names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- Zyclara37.5 mg/g, 2.5 mg/g · bausch health us, llc
Canada
- ALDARA P
- ZYCLARA
- VYLOMA